OverT Bio Announces the Formation of the Clinical Advisory Board to Support the Clinical Developm...
OverT Bio forms Clinical Advisory Board to advance OVT-101, a scalable CAR-T therapy targeting CLDN6 for ovarian and other solid tumors.
businesswire.com